Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVNGet Free Report) in a note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price objective on shares of Trevena from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 16th.

Check Out Our Latest Stock Report on TRVN

Trevena Stock Performance

Trevena stock opened at $0.39 on Friday. The firm has a market capitalization of $7.15 million, a PE ratio of -0.15 and a beta of 1.11. Trevena has a one year low of $0.30 and a one year high of $1.35. The stock’s 50 day moving average price is $0.41 and its 200 day moving average price is $0.55. The company has a debt-to-equity ratio of 8.35, a quick ratio of 3.60 and a current ratio of 3.60.

Trevena (NASDAQ:TRVNGet Free Report) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.01. The firm had revenue of $0.02 million for the quarter. As a group, sell-side analysts expect that Trevena will post -1.29 EPS for the current fiscal year.

Institutional Trading of Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC bought a new position in Trevena, Inc. (NASDAQ:TRVNFree Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned approximately 0.32% of Trevena at the end of the most recent quarter. Institutional investors and hedge funds own 13.56% of the company’s stock.

About Trevena

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Further Reading

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.